Michael Kimelman

Michael Kimelman discloses dealings in Igene Biotechnology Inc to SEC (Form 4). Over a trading history stretching from 9 December 2008 to 20 October 2010, the count stands at 4 filings.

No open-market purchase appears, only 1 sale worth €17k. Outside the open market, there are 3 option exercises. 2010 to date brings no purchases and 1 sale.

The newest entry dates from 21 October 2010: an open-market sale of €17k, in Igene Biotechnology Inc. Typically, a trade is published a median of 7 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.